A Phase 3 switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late-onset Pompe Disease
Trial ID or NCT#
NCT01924845
Status
NOT RECRUITING
Purpose
To study the safety and efficacy of the study medication, BMN 701 in patients with late onset Pompe Disease.
Investigator(s)
John W. Day, MD, PhD
View on